Summary of GlobalFoundries Conference Call Company Overview - **Company**: GlobalFoundries (NasdaqGS: GFS) - **Date**: March 04, 2026 - **Speakers**: Tim Breen (CEO), Sam Franklin (CFO) Key Industry Trends - **Demand Trends**: - Significant acceleration in data center requirements and deployments globally, creating bottlenecks in power and networking [2][3] - Long-term trend of AI integration into various sectors, including automotive and home environments, driving demand for semiconductors [3][4] - **Supply Trends**: - GlobalFoundries is positioned uniquely due to its secure manufacturing footprint, which is increasingly essential for applications [3][4] M&A Strategy - Recent acquisitions (MIPS and Synopsys' ARC business) aimed at enhancing technology differentiation and customer engagement [9][10] - Focus on providing a full spectrum of services beyond manufacturing, including processor IP and custom silicon [9][10] Financial Performance - Gross margins have improved, with a long-term target of 40% [101][102] - Revenue from automotive and data center sectors has grown significantly, contributing to a more balanced revenue mix [102][104] - The company aims for $1 billion in revenue by 2030, with a run rate expected by the end of 2028 [72][121] Capital Expenditure and Growth - Increased capital intensity expected in 2026, targeting 15%-20% of revenue for CapEx [116][118] - Investments focused on debottlenecking capacity and enhancing existing facilities [111][112] - Government partnerships are crucial for capital efficiency, with expectations of receiving $0.30 to $0.55 for every dollar invested [113][114] Market Dynamics - The automotive sector has shown consistent growth, with GlobalFoundries outpacing market growth rates [89][93] - The company has established strong relationships with automotive OEMs, which are critical for long-term partnerships [99][100] - Demand for silicon photonics and co-packaged optics is expected to grow, with projections for significant revenue increases in these areas [44][50] Competitive Positioning - GlobalFoundries emphasizes its technology roadmap, ecosystem development, and manufacturing capabilities as key competitive advantages [58][60] - The company is well-positioned to meet the increasing demand for high-performance semiconductors, particularly in data centers [58][60] Conclusion - GlobalFoundries is at a pivotal moment, leveraging trends in AI and data centers to drive growth - The company is focused on enhancing its technology offerings and expanding its market presence through strategic acquisitions and partnerships - Investors are encouraged to recognize the long-term potential of GlobalFoundries as it navigates a rapidly evolving semiconductor landscape [121][122]

Arrow Electronics FY Conference Summary Company Overview - **Company**: Arrow Electronics (NYSE: ARW) - **Industry**: Electronic Component Distribution - **Market Position**: Largest global components distributor with a diversified business model, addressing a $30 billion market in electrical components, semiconductors, and technology solutions [5][6] Key Points and Arguments Financial Performance - **Revenue Composition**: 75% hardware and 25% software [6] - **Cost Management**: Fixed costs reduced by approximately 10% over the last few years while variable costs have also decreased despite revenue growth [9] - **Backlog and Demand**: Increasing backlog with better visibility extending into the third quarter, indicating real demand rather than just price increases [10][11] - **Book-to-Bill Ratio**: Greater than 1-to-1 across all regions, a significant improvement compared to previous quarters [11] Market Trends - **Cyclical Recovery**: Early stages of a cyclical turn in the semiconductor market, with positive indicators for demand across various verticals [12][34] - **Geographic Demand Trends**: - East Asia shows early recovery, followed by EMEA and North America [27] - Growth in aerospace, defense, and industrial markets, particularly in North America and EMEA [29][33] - Transportation sector showing signs of recovery, especially among tier one and tier two suppliers [33] Customer and Supplier Dynamics - **Customer Diversification**: No single customer accounts for more than 2% of revenue, ensuring a broad-based customer base [38] - **Supplier Exposure**: No supplier exceeds 8% of revenue, contributing to a well-diversified supply chain [46] - **China Exposure**: Less than 10% of overall revenue is derived from Asia-Pacific, indicating limited risk from geopolitical tensions [52] Value-Added Services - **Supply Chain Management**: Arrow manages complex supply chains for large customers, enhancing operational efficiency and generating fee-based income [118][120] - **Demand Creation**: Arrow employs engineers to assist customers in product design, facilitating faster market entry [129] - **Digital Test Drive**: A new initiative allowing virtual testing of products, reducing physical component damage and speeding up design processes [133] ECS Business Segment - **ECS Overview**: Comprises 75% software distribution, countercyclical to the semiconductor business, providing stability and higher margins [163][165] - **Beyond Distribution**: A model where Arrow takes on the commercial arm for infrastructure software providers, allowing them to focus on internal development [170][172] Future Outlook - **Margin Improvement**: Value-added services have increased their contribution to operating income from 20% to 30% over the last few years, with margins significantly higher than traditional distribution [150][153] - **AI and Software Trends**: Arrow is positioned well in the technology infrastructure side of software, which is expected to grow alongside AI developments [186][192] Additional Important Insights - **CEO Transition**: Ongoing search for a new CEO with a focus on operational capabilities rather than purely sales experience [16][17] - **Geopolitical Risks**: Minimal impact from tariffs, with only about 1% of revenue affected by tariff-related costs [92] - **Flexibility in Operations**: Arrow has demonstrated adaptability in warehousing and distribution, particularly in response to changing market demands [95][108] This summary encapsulates the key insights from Arrow Electronics' FY conference, highlighting the company's strong market position, financial health, and strategic initiatives aimed at leveraging growth opportunities in the electronic components industry.

Summary of ScanSource Conference Call Company Overview - **Company**: ScanSource - **Industry**: Technology Distribution - **Annual Revenue**: Approximately $3 billion [3] - **Employee Count**: About 2,100 [3] - **Geographic Focus**: 92% of revenue generated in North America, with some presence in Brazil [4] Core Business Model - **Two-Tier Distribution Model**: Works directly with technology manufacturers to sell to resellers, who then support end users [3] - **Specialization**: Focuses on complex core business technologies across various verticals, including mobility, barcode technology, physical security, point-of-sale systems, and networking [4][5][6] Financial Performance - **Gross Profit Margin**: Increased from 10% to over 13.5% due to the introduction of recurring revenue streams [8] - **Recurring Revenue**: Currently, about one-third of gross profits come from recurring revenue, with a target to increase this to 50% [9][10] - **EBITDA Margins**: Expected to grow from just under 5% to closer to 6% over the next three years [21] Strategic Goals - **Growth Projections**: Anticipates a growth rate of 5%-7% over the next three years, slightly above GDP growth [20] - **Free Cash Flow**: Aims for at least 80% conversion of net income to free cash flow [21] - **Capital Allocation**: Focus on disciplined capital allocation, including potential acquisitions and share repurchases [19][30] Market Dynamics - **Technology Tailwinds**: Benefiting from trends in cloud adoption, AI, and security technologies [15] - **Supply Chain Management**: Adjusted strategies during COVID-19 to focus on fulfilling orders rather than holding inventory [27] - **Vendor Relationships**: Currently not experiencing margin clawbacks from suppliers, maintaining a favorable position due to low inventory levels [41][43] Challenges and Considerations - **Demand Uncertainty**: Some concerns about demand fluctuations due to economic conditions, but no significant impacts observed yet [39] - **AI Integration**: Exploring opportunities to deploy AI for cost savings and revenue generation, while assessing commercially viable AI vendors [63][65] Key Takeaways - **Business Transformation**: ScanSource has evolved from a traditional hardware distributor to a specialized technology distributor with a focus on recurring revenue and improved financial metrics [66] - **Investor Communication**: Emphasizes the importance of transparency and disciplined capital allocation to enhance shareholder value [26][19]

Scholar Rock (NasdaqGS:SRRK) FY Conference Summary Company Overview - Scholar Rock is focused on developing innovative therapies targeting muscle-related diseases, particularly Spinal Muscular Atrophy (SMA) through its anti-myostatin pipeline, including the drug apitegromab [3][4] Key Value Creation Milestones - The company anticipates a transformative year in 2026 with the expected regulatory approvals for apitegromab in the US and Europe, aiming to establish a commercial presence in 50 countries [4][19] - Plans to develop apitegromab and a second myostatin inhibitor, SRK-439, for various severe and rare neuromuscular disorders [5][6] Regulatory and Manufacturing Updates - The initial launch of apitegromab was expected in 2025 but faced delays due to compliance issues at the manufacturing facility in Indiana, owned by Novo Nordisk [12][13] - The FDA granted a priority review for the drug, with an action date of September 22, 2025, but a complete response letter was received due to manufacturing facility compliance issues [12][14] - Positive progress has been made in remediating the facility, with a successful Type A meeting with the FDA and ongoing inspections [16][17] - The company is also preparing a second fill-finish facility to ensure supply chain robustness, which could support a 2026 launch even if the Indiana facility inspection does not go as planned [18][45] Market Opportunity and Pricing Strategy - Scholar Rock sees a multi-billion dollar opportunity in the SMA market alone, with a patient population of approximately 35,000 globally [6][50] - Pricing strategy will consider the rarity and severity of SMA, the impact of the drug on motor function, and the competitive landscape of existing therapies [51][52] Launch Strategy and Patient Engagement - The company expects robust demand for apitegromab, particularly from patients currently on therapy, with over 90% of trial participants remaining in long-term studies [53][54] - Initial launch uptake may be tempered by prior authorization requirements and medical policies from payers, but the company is optimistic about converting enrollment forms into reimbursed patients over time [56][57] Future Developments - Scholar Rock is also exploring a subcutaneous formulation of apitegromab and a next-generation myostatin inhibitor, SRK-439, which shows promise in early trials [58][61] - The company has initiated a Phase 2 study for Facioscapulohumeral Muscular Dystrophy (FSHD), with plans to dose patients later this year [64][65] Conclusion - Scholar Rock is positioned to become a significant player in the biotech space with its innovative therapies targeting muscle diseases, particularly SMA, while navigating regulatory challenges and preparing for a robust market entry in 2026 [4][19][56]

Sutro Biopharma FY Conference Summary Company Overview - **Company**: Sutro Biopharma (NasdaqGM:STRO) - **Event**: FY Conference held on March 04, 2026 - **CEO**: Jane Chung Key Points Strategic Transformation - Sutro has undergone significant transformation over the past year, including right-sizing the team and extending its operational runway multiple times, now projected into Q2 2028 [4][5][6] - The company is focused on delivering next-generation antibody-drug conjugates (ADCs) and has accelerated its clinical programs, with plans to file three Investigational New Drug (IND) applications over the next two years [5][6] Unique Technology and Pipeline - Sutro's ADC technology is differentiated by its ability to optimize all components of an ADC, including antibody, linker, and payload, which enhances both safety and efficacy [6][7] - The company has developed a pipeline that includes both single and dual payload ADCs, with a focus on overcoming resistance seen in conventional ADCs [8][12] Clinical Programs - **STRO-004**: A tissue factor ADC program currently in clinical trials, with a high safety window at a dose of 50 mg/kg, significantly higher than competitors [9][18] - **STRO-006**: An integrin beta-6 program targeting lung cancer, showing promising safety profiles [10] - **PTK7 Dual Payload Program**: Accelerated from late 2027 to later this year, with a DAR 10 design [10] Efficacy and Safety - Sutro's ADCs have shown to increase drug exposure by 2-3 times compared to conventional ADCs, potentially leading to better safety and efficacy profiles [8] - The company aims to maintain low toxicity levels, particularly concerning interstitial lung disease (ILD) and bleeding risks, with a target of low single-digit ILD rates for STRO-004 [24][25] Competitive Landscape - Sutro's technology is positioned to be competitive due to its advanced payload modalities and the ability to control payload ratios, which is crucial for safety in dual payload ADCs [12][13][40] - The company is addressing the limitations of existing ADCs, such as TIVDAK, by improving tolerability and safety profiles [20][21] Future Outlook - Sutro is optimistic about the potential of its ADCs to become a standard of care in oncology, with ongoing efforts to enhance the therapeutic safety window and efficacy [36][38] - The company emphasizes the importance of flexibility in its platform technology, allowing for rapid development and adaptation of new ADC constructs [46] Management and Execution - The new management team is focused on execution and operational discipline, aiming to connect discovery, process development, and clinical development efficiently [44][45] - The transformation under CEO Jane Chung is recognized as a significant turnaround for the company, with a renewed focus on its technology and market strategy [44][45] Additional Insights - Sutro's ability to generate new ADC constructs quickly is highlighted as a competitive advantage, potentially leading to faster clinical readiness [46] - The company acknowledges the historical challenges faced by ADCs regarding toxicity and aims to address these through innovative design and technology [34][35]

Summary of Passage Bio FY Conference Call Company Overview - **Company**: Passage Bio (NasdaqGS:PASG) - **Focus**: Development of gene therapies for neurodegenerative diseases, specifically targeting Frontotemporal Dementia (FTD) with granulin mutation and Huntington's disease Key Points Clinical Programs - **FTD-GRN Program**: - Targets Frontotemporal Dementia (FTD) with granulin mutation affecting approximately 18,000 patients in the U.S. and Europe [2] - FTD is characterized by early-onset behavioral dementia with no current treatment options, leading to an average lifespan of eight years post-diagnosis [2] - The program aims to address low levels of progranulin, a protein critical for lysosomal function, which is deficient in these patients due to granulin gene mutation [2][3] - The AAV1 gene therapy product aims to replace the missing progranulin to improve neurodegeneration outcomes [3] - **Study Progress**: - Nine patients have been treated in the ongoing Phase 1/2 study, with modifications to inclusion criteria to focus on milder cases of FTD [4] - The study is assessing safety, tolerability, and biomarkers such as CSF progranulin levels, plasma neurofilaments, and volumetric MRI [5][6] - Initial data shows that higher doses of the therapy significantly elevate CSF progranulin levels, with expectations for lower doses to also show positive trends [8][9] - **Safety Profile**: - Three serious adverse events (SAEs) were reported at the higher dose, leading to a shift to a lower dose and the introduction of prophylactic anticoagulation [10][12] - The safety profile remains a critical focus as the company prepares for regulatory discussions [39] Competitive Landscape - **Comparison with Other Therapies**: - Passage Bio's approach is differentiated from other therapies, such as the anti-sortilin antibody therapy, which did not meet endpoints in clinical trials [23] - The company emphasizes the importance of patient selection and the mechanistic differences in their therapy compared to competitors [24][28] Future Outlook - **Regulatory Strategy**: - The company is seeking early regulatory feedback on the registrational path for FTD-GRN, considering both single-arm and randomized controlled study designs [38] - Plans to declare a clinical candidate for Huntington's disease in the second half of the year, with ongoing discussions about the development path [16][52] - **Enrollment and Interest**: - Enrollment for the FTD-GRN cohort has been brisk, with increased interest following the discontinuation of other studies in the space [44][50] - The company is optimistic about the momentum in patient recruitment due to the unmet need in the orphan indication [50] Manufacturing and Partnerships - **Manufacturing Process**: - The company has established an efficient manufacturing process for its gene therapies, which is crucial for scaling production [59] - Current manufacturing capabilities are focused on the FTD program, with plans to expand as the Huntington's program develops [60] Additional Insights - The company is committed to addressing neurodegenerative diseases through innovative gene therapy approaches, with a focus on safety and efficacy as they navigate regulatory pathways and clinical development [59][60]

Summary of Crinetics Pharmaceuticals FY Conference Call Company Overview - **Company**: Crinetics Pharmaceuticals (NasdaqGS:CRNX) - **Founded**: 2008 with a mission to be the world's leading endocrine company - **First Drug**: Approved for acromegaly, launched in 2025, generating $5.4 million in revenue from over 200 start forms [4][6] - **Pipeline**: Diverse pipeline including drugs for carcinoid syndrome, congenital adrenal hyperplasia (CAH), and Cushing's disease [5][19] Key Points Product Launch and Revenue - **PALSONIFY**: First drug launched, expected to be the standard of care for acromegaly, with strong early demand and over 200 enrollments [6][8] - **Revenue Generation**: $5 million in product revenue in the first quarter, with a pricing of $290,000 for a year of therapy [9][37] - **Reimbursement Process**: Over 50% of patients quickly reimbursed through medical exemption forms; average duration for prior authorizations is about 12 months [9][30] Clinical Trials and Pipeline - **Atumelnant**: An ACTH receptor antagonist in advanced clinical trials for CAH and Cushing's disease, with promising phase 2 data [7][19] - **Paltusotine**: Being studied for carcinoid syndrome, with phase 3 trials initiated; aims to simplify treatment compared to traditional painful injections [20][22] - **CRN09682**: A novel small molecule targeting neuroendocrine tumors, currently in first-in-human phase 1 dose escalation [24][80] Market Potential and Strategy - **Market Size**: Global market for somatostatin receptor ligands (SRLs) is approximately $2.5 billion, with $800 million to $900 million attributed to acromegaly [54] - **Patient Retention**: 80% of patients on SRLs discontinue or switch within five years, indicating a significant opportunity for PALSONIFY to retain patients [64] - **European Approval**: Positive recommendation from CHMP for European approval expected by mid-2026; plans to launch country-by-country [39][40] Future Milestones - **Upcoming Data**: Additional data from ongoing studies expected throughout the year, including updates on atumelnant and CRN09682 [25][81] - **Preclinical Programs**: Progress on TSH receptor antagonist and PTH receptor antagonist, with potential IND filings anticipated next year [84] Additional Insights - **Patient Experience**: Paltusotine offers a once-a-day oral administration, significantly improving patient experience compared to traditional therapies [20][41] - **Regulatory Landscape**: The company is navigating a changing regulatory environment, particularly concerning pricing and reimbursement strategies [39][40] - **Market Execution**: The success of PALSONIFY's launch and the ability to convert patients to paid drug status will be critical for market capture [61][62]

Asana 2026 Conference Summary Company Overview - Asana (NYSE: ASAN) is a collaborative work management platform with 170,000 customers globally, including 85% of the Fortune 500 [5][6] - The company aims to pioneer the "agentic enterprise," where humans and AI agents collaborate effectively [8][9] Core Strategies and Products - **Agentic Enterprise Vision**: Asana positions itself as a foundational layer for collaboration between humans and AI agents, emphasizing the need for structured coordination as the complexity of tasks increases [9][10] - **AI Products**: - **AI Teammates**: Currently in beta with over 200 customers, set to launch generally in March. These agents are designed for specific departments and utilize the Work Graph for immediate productivity [11][12] - **AI Studio**: Launched last year, it has reached over $6 million in Annual Recurring Revenue (ARR) within a year. It integrates AI into workflows for tasks like quality checks and routing [13][14] Financial Performance - **Q4 Results**: Asana reported a 9.2% revenue growth, with a 13% free cash flow margin for the quarter, marking a 700 basis point improvement year-over-year [30][31] - **Guidance for FY27**: Revenue growth is projected at 8% with margins of at least 9.5%. The company is cautious due to headwinds in the Product-Led Growth (PLG) segment [32][34] Market Position and Competitive Landscape - Asana differentiates itself through its Work Graph architecture, which allows for persistent memory and context in task management, setting it apart from competitors like Microsoft [24][25] - The company has established a strong customer base, including leading AI labs, which enhances its credibility and market position [20][21] Customer Engagement and Retention - Asana has seen strong net retention rates, particularly among its largest customers, with top 10 renewals exceeding 100% NRR [30][39] - The introduction of AI products is expected to mitigate potential downgrades during renewal conversations, as they provide value independent of seat counts [41][42] Operational Efficiency and Internal Use of AI - Asana utilizes its own AI products across various departments, driving productivity and innovation [43][44] - The company is committed to further embedding AI tools into its processes to enhance operational efficiency [44] Capital Allocation Strategy - Asana has increased its buyback authorization to $200 million, viewing share repurchase as an attractive capital allocation strategy [48][49] - The company remains open to opportunistic M&A, focusing on tuck-in acquisitions to enhance technology and talent [48] Conclusion - Asana is positioned to leverage its innovative AI products and strong customer relationships to drive future growth, while maintaining a focus on operational efficiency and strategic capital allocation [49]

Charter Communications Conference Call Summary Company Overview - **Company**: Charter Communications (NasdaqGS:CHTR) - **Focus for 2026**: Return to broadband growth, sustainable EBITDA, and free cash flow growth [3][4] Key Points Strategic Focus - **Broadband Growth**: Priority to return to broadband growth, with significant investments in rural build and network evolution nearing completion [3][4] - **Value Messaging**: Emphasis on improving messaging around value and service reputation to enhance customer relationships [4][10] Competitive Positioning - **America's Connectivity Company**: Branding emphasizes 100% U.S.-based sales and service, reliability guarantees, and significant savings for customers [5][10] - **Convergence Strategy**: Charter offers convergence across its entire footprint, providing faster speeds and mobile services, which is a competitive advantage [23][24] New Leadership - **Hiring of COO**: Nick Jeffery, with experience in competitive wireless markets, is expected to enhance messaging and service reputation [14][16] Market Challenges - **Housing Market Impact**: Lower housing starts and macroeconomic factors are affecting customer movement and acquisition opportunities [33][35] - **Fixed Wireless Access Competition**: New competition from fixed wireless access is noted, although Charter maintains higher penetration in mature fiber markets [27][28] Product Innovations - **Invincible WiFi**: New product using Wi-Fi 7 with 5G backup aims to improve service reputation and reduce trouble calls [37][44] - **$1,000 Annual Savings Guarantee**: Aimed at enhancing customer value perception, with a strong track record of delivering savings [48][61] Wireless Business Growth - **Mobile Strategy**: Significant growth expected in the wireless segment, leveraging MVNO relationships and superior connectivity through Wi-Fi and CBRS [66][70] - **Brand Awareness**: Need for increased brand awareness to promote mobile offerings effectively [82] Video Business - **Video Strategy**: Focus on supporting broadband connectivity rather than seeking growth in video; improvements in packaging and value offerings noted [86][90] Commercial Business - **Small Business Challenges**: Similar competitive pressures as residential; potential for growth with Invincible WiFi [97] - **Enterprise Growth**: Gaining credibility in the enterprise space with advanced products and larger customers [98] Financial Outlook - **CapEx Guidance**: Long-term CapEx expected to decrease to below $8 billion by 2028, with a focus on maintaining network superiority [124][130] - **Leverage Framework**: Reduced long-term leverage target to 3.5 to 3.75 times, aimed at improving shareholder confidence [148][153] Conclusion - **Commitment to Growth**: Charter is focused on returning to broadband growth, enhancing service reputation, and leveraging past investments to drive future success [157]

Texas Instruments Conference Call Summary Company Overview - **Company**: Texas Instruments (NasdaqGS:TXN) - **Date**: March 04, 2026 - **Speaker**: CEO Haviv Ilan Key Points Industry and Market Segments - Texas Instruments is in the last year of a 6-year investment cycle, executed ahead of schedule and on budget [3] - The company has reorganized its market segments to include: - Industrial - Automotive - Data Center - Personal Electronics - Communications [5][7] - The focus is on industrial, automotive, and data center markets, which account for 75% of the business and are expected to drive growth [7] Financial Performance and Projections - Texas Instruments aims to grow free cash flow per share, targeting at least $8 per share in 2026 with potential for upside [8] - The company reported a 13% growth in 2025, with expectations for continued recovery in 2026 [37] M&A Strategy - The acquisition of Silicon Labs is a strategic move to enhance Texas Instruments' capabilities in analog and mixed-signal technologies, particularly in the industrial sector [12][14] - The company sees potential revenue synergies from integrating Silicon Labs' products into its existing portfolio [13] Competitive Positioning - Texas Instruments emphasizes its competitive advantages in manufacturing, technology, and a broad product portfolio [3] - The company is focused on maintaining a balance between general-purpose and application-specific products to capture growth in key markets [25][29] Inventory and Capacity Management - Texas Instruments plans to maintain inventory levels between 150-250 days to prepare for demand surges, a strategy refined during the COVID-19 pandemic [55][60] - The company aims to operate at 80%-90% capacity to ensure efficiency while being prepared for demand fluctuations [52][56] Market Dynamics - The data center segment is growing rapidly, now accounting for 10%-11% of revenue and growing at 70% year-over-year [40] - Industrial markets are currently below trend line but are expected to recover, with a 20% year-on-year growth observed in Q4 [68][71] - The automotive market has shown resilience, with a 12% CAGR over the past 12 years, driven by content addition across various vehicle sectors [90] Challenges and Opportunities - Competition in China is intensifying, but Texas Instruments has managed to grow its market share, achieving over 25% growth in 2025 [102][105] - The company is focused on capital allocation towards R&D in data centers to meet the demands of higher power density and consumption [109] Future Outlook - Texas Instruments is optimistic about the recovery in industrial markets and the continued growth in automotive and data center sectors [73][100] - The company is preparing for various market scenarios to ensure readiness for potential demand surges in 2026 [35][66] Additional Insights - The company maintains a disciplined approach to capital management, focusing on optimizing cash flow and strategic investments [9][44] - Texas Instruments is committed to building its microcontroller portfolio organically, with plans to enhance capabilities in embedded markets [118][125]